Studying on countermeasures for deep processing of edible fungi in Gutian County

食用菌产业是古田县的支柱产业,发展精深加工对促进古田县食用菌产业转型升级具有重要意义。该文分析了古田县食用菌产业的发展现状及精深加工存在的主要问题,提出推动古田县食用菌产业向精深加工发展的对策。Mushroom industry is a pillar industry of Gutian County,to develop its deep processing had great significance to promote the transformation and upgrading of edible fungus industry.This paper analyzed present situation of edible mushroom industry development in Gutian County and the main problem in pushing on the development of deep processing,and put forward countermeasures for promoting the mushroom industry towards deep processing in Gutian County

线蚓科分类学研究进展

线蚓科隶属于环节动物门环带纲,迄今共记录32属650余种,是该纲的第二大科。它们广泛分布于土壤、海洋、淡水、河口和冰川等。其中,约2/3的线蚓科物种(近500种)为陆生种类,100余种仅分布在海洋中。尽管经历了200多年的探索,线蚓科仍然是认知最少的类群之一。尝试回顾人类对线蚓科环带动物分类学和系统发育学方面的认知历程和积累的知识体系,描述线蚓科关键的形态学分类特征以及线蚓科分类研究遇到的主要问题和障碍,展望了线蚓科分类学未来的研究方向。线蚓科的分类研究尚处于α分类阶段,体现在以物种探索为主和大量的已描述的物种需要验证等。而基于生物学物种概念(生殖隔离)的线蚓科物种探索,虽然有一些合理的逻辑解释,但缺乏严格的科学验证。线蚓科内多数属为复系,表明已建立的线蚓科分类系统仍然不能很好的反映线蚓科的自然进化历史。线蚓科分类面临的主要问题和障碍是未描述种类亟待发掘、已描述的物种需要验证、属/种的厘定以及现代属级概念的建立、DNA分类在线蚓科的应用和线蚓科内的系统发育关系研究亟待开展,以及物种探索的不平衡、经费和研究人才匮乏以及网络分类的缺失等。将分子学数据和系统发育物种概念纳入线蚓科的分类学研究,应该是线蚓科分类的一个方向。通过解读保守基因的信息,可以揭示线蚓科的祖先与它们生活的古环境长期斗争的历史,以及将优良的性状遗传给后代的过程和驱动力。而系统发育物种概念认为物种是拥有共同祖先的,物种仅能通过生殖隔离与系统发育重建一起加以验证。基于系统发育物种概念而构建的线蚓科分类系统,必将能真实的反映线蚓科内各分类单元的亲缘关系和进化轨迹。而将最新的线蚓科分类学知识传播于分类学知识的终端使用者,是线蚓分类学家的职责。这些知识将有助于提高人们对线蚓类在生态系统中功能的了解,如土壤有机质分解、养分矿化和健康评价以及评估气候变化等

~（19）F＋~（45）Sc深非弹反应产物的激发函数

测量了１０２ＭｅＶ到１０８ＭｅＶ（１９）Ｆ＋（４５）Ｓｃ反应在θ１＝２６°和θ１＝４２°的耗散部分产物的激发函数，能量步长３００ｋｅＶ，靶厚５３μｇ／ｃｍ２．用统计理论求得了各元素的能量相干宽度Γ，提取了反应的特征时间τ，探讨了耗散反应机制．Excitation functions have been measured for the dissipative reaction products at θl= 26° and θl= 42° in tEe 102 MeV to 108 MeV 19F8+ + 45Sc reactions by a step of 300 keV. The energy coherence widths and the dinuclear system lifetimes are extracted by analysing the cross section fluctuations. The dissipative reaction mechanisms are investigated.国家自然科学基

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials